aiMOOC

Aging – FGF17 and the limits of molecular rejuvenation

QR-Code

Introduction

In 2022, Tal Iram and colleagues reported that cerebrospinal fluid from young mice, delivered directly into the ventricles of aged male mice, altered the aged hippocampal environment, increased oligodendrocyte-lineage responses, and improved a remote fear-memory readout. The study then nominated fibroblast growth factor 17, FGF17, as one candidate signal linking young CSF to serum response factor, SRF, activity in oligodendrocyte progenitor cells. The paper became a prominent example of “molecular rejuvenation”, but that phrase compresses several distinct claims that must be separated if you want to reason causally.

This expert colloquium reconstructs the study rather than repeating its headline. You will distinguish oligodendrogenesis, myelination, remote memory recall, and general performance; inspect the published correction; search for same-context replication and cross-model corroboration; and design experiments that can test necessity, sufficiency, mediation, durability, and safety.

The central rule is simple: an intervention can change one biological layer without proving that it caused a change in another. More proliferating OPCs do not automatically imply more functional myelin; more myelin does not automatically prove better memory; more freezing during a fear-memory test does not establish broad cognitive rejuvenation; and a mouse intervention does not establish a human treatment.

Learning Objectives

After completing this aiMOOC, you should be able to:

Experimental design: Reconstruct the sequence, comparison groups, timing, and outcome measures in the 2022 Iram study.
Oligodendrogenesis: Distinguish OPC proliferation, lineage differentiation, mature oligodendrocytes, and myelin formation.
Memory consolidation: Explain what the remote fear-memory paradigm measured and what it did not establish.
Causal inference: Separate necessity, sufficiency, mediation, association, and translational plausibility.
Replication: Distinguish direct independent replication from mechanistic extension and cross-disease corroboration.
Translational medicine: Grade mouse evidence, human associations, and hypothetical clinical transport separately.

Conceptual Map: Four Outcomes That Must Not Be Collapsed

Oligodendrogenesis

Oligodendrogenesis is the production and maturation of cells in the oligodendrocyte lineage. An OPC can proliferate without becoming a mature oligodendrocyte, and a newly differentiated oligodendrocyte can exist without establishing enough new compact myelin to change circuit function. Therefore, EdU or BrdU incorporation in OPCs is an early cellular endpoint, not a synonym for remyelination.

In Iram et al. 2022, young CSF increased proliferation of hippocampal OPCs in aged mice. Primary rat OPC cultures exposed to young human CSF also showed increased proliferation and differentiation-related changes. Recombinant Fgf17 increased OPC proliferation in aged mouse hippocampus in vivo and increased proliferation and differentiation in cultured rat OPCs. These are related but non-identical observations.

Myelination

Myelination is a structural tissue outcome. In the 2022 study, after young-CSF-treated proliferating cells were allowed to mature for three weeks, the investigators reported increased hippocampal MBP signal and more myelinated axons by transmission electron microscopy in the molecular layer. These measurements strengthen the claim that young CSF affected the myelin compartment.

The critical limitation is that the paper did not directly demonstrate that Fgf17 alone increased aged hippocampal myelination in vivo by the same structural readouts. Fgf17-alone sufficiency was shown for aged-mouse OPC proliferation and for the remote memory readout, while Fgf17 promoted OPC differentiation in vitro. Treating those observations as proof that Fgf17 caused new functional myelin in aged mice would bridge an untested step.

Memory Recall

The aged-mouse behavioral result was not a generic “cognition score.” Twenty-month-old mice first learned a fear-conditioning association involving a cage context, an audiovisual cue, and foot shock. The intervention followed learning. Young mouse CSF or recombinant Fgf17 was infused for seven days, and remote recall was assessed about three weeks after acquisition.

On the remote test day, contextual freezing did not differ significantly between treatment groups. The reported benefit concerned cued freezing in a novel context after the audiovisual cue. This makes the strongest narrow description “better preservation or expression of remote cued fear memory under this paradigm,” rather than “general cognitive rejuvenation.”

General Performance Changes

A fear-conditioning endpoint can be influenced by more than memory. Auditory and visual cue detection, nociception, shock reactivity, locomotion, anxiety-like behavior, baseline freezing, illness, motor capacity, and exploration can all change the measured behavior. The core aged Fgf17 experiment did not constitute a broad battery demonstrating generalized improvement across cognition, motor function, sensory function, and affect.

Young mice given an Fgf17-blocking antibody were tested in a forced-alternation Y-maze and fear conditioning, but that is a different causal question in a different age condition. It cannot be used as if it were a broad-performance battery after Fgf17 treatment in aged mice.

Reconstructing Iram et al. 2022

The Primary Paper

The primary article is Tal Iram et al., “Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17,” Nature 605, 509–515, published 11 May 2022, DOI 10.1038/s41586-022-04722-0. All animal experiments reported in the Methods used male mice. Aged C57BL/6 mice were 18–22 months old; young mice were generally about two months old.

The study combined multiple levels of evidence: CSF transfer, hippocampal transcriptomics, histology, electron microscopy, primary OPC culture, nascent-RNA analysis, reporter assays, receptor-blocking experiments, recombinant growth-factor infusion, antibody blockade, and behavior. That breadth is valuable, but it also creates a temptation to narrate every result as one continuous causal chain. Your task is to resist that temptation until each link has been tested.

Young-CSF Intervention

For the main infusion paradigm, pooled young mouse CSF or artificial CSF was delivered intracerebroventricularly for seven days using an osmotic pump at 0.5 microlitres per hour. The behavioral experiment began with fear learning before the infusion. Remote recall was then assessed on day 22.

The remote memory comparison shown in Figure 1b used 10 artificial-CSF controls and 8 young-CSF mice after one death in each group. The paper reported higher cue-related freezing in the young-CSF group. Importantly, the Methods state that there was no significant group difference in contextual fear conditioning on day 22.

Bulk hippocampal RNA sequencing after young-CSF exposure identified 271 differentially expressed genes at the authors’ false-discovery threshold, with oligodendrocyte-associated genes prominent among the changes. This transcriptomic result nominates a responding lineage; it does not by itself prove that those transcriptional changes mediate behavior.

Human-CSF Transfer into Mice

A separate mouse experiment compared pooled CSF from healthy young and older human donors. Young human CSF induced more hippocampal OPC proliferation than aged human CSF in the recipient mice. This is biologically interesting but is still a mouse intervention: the recipient brain, route, dose environment, and outcome remain preclinical.

Do not misclassify this experiment as evidence that administering young human CSF to older people improves cognition. No such human treatment inference follows from a cross-species infusion into mice.

FGF17 Candidate Selection and Pathway

The investigators linked young-CSF responses to SRF, a transcription factor associated with actin-cytoskeleton regulation. They screened CSF candidates capable of activating an SRE reporter and focused on Fgf17 because it was brain-enriched and showed age-related decline signals. In reporter experiments, Fgf17 activation depended on Fgfr3 blockade conditions, suggesting an FGF17–FGFR3 route into downstream signaling.

Recombinant mouse Fgf17 was infused intracerebroventricularly at 25 micrograms per millilitre for seven days at 0.5 microlitres per hour. In aged mice, Fgf17 increased hippocampal OPC proliferation and improved the same remote fear-memory endpoint. The reported in-vivo OPC comparison used 8 artificial-CSF controls and 6 Fgf17 mice; the remote-memory comparison used 10 controls and 11 Fgf17-treated mice after attrition.

Sufficiency in this context means that adding Fgf17 was enough to reproduce selected endpoints under these experimental conditions. It does not mean that Fgf17 is the only active component of young CSF or that it explains every young-CSF effect.

What the Blockade Experiment Actually Tests

The paper infused an anti-Fgf17 antibody into young mice. Those young mice showed impairments in a Y-maze task and contextual fear conditioning relative to an antibody control. In cultured OPCs, anti-Fgf17 also reduced young-CSF-induced OPC proliferation.

These experiments support a role for endogenous Fgf17 in young-mouse cognitive function and support Fgf17 participation in the OPC culture response. However, they do not directly test the key rejuvenation necessity question: Does neutralizing Fgf17 abolish the benefit of young CSF in aged mice? That experiment would require aged recipients receiving young CSF plus control antibody versus young CSF plus Fgf17 neutralization.

This distinction matters because a molecule can be necessary for normal function in a young system yet dispensable for the effect of a complex rejuvenating mixture in an old system, where redundant signals may exist.

Published Correction

The correction was published online on 13 December 2022 and appeared in Nature 613, E1 in January 2023: Author Correction.

The correction states that several figure P values had been incorrectly truncated, that one P value in Figure 2e was missing a zero, and that Figure 2i was corrected from 0.003 to 0.011 while the analysis was corrected to a two-way ANOVA rather than a t-test. The authors stated that the conclusions were unaffected, and the online figures were updated.

For a claim audit, the correct response is neither to ignore the correction nor to treat any correction as automatic invalidation. You should:

Statistical reporting: Use the corrected article as the evidentiary record.
Effect size: Ask for effect magnitudes and uncertainty, not only thresholded P values.
Multiplicity: Track how many outcomes and comparisons were tested.
Robustness: Ask whether conclusions survive reasonable analytic alternatives.
Replication: Treat independent reproduction as stronger evidence than corrected significance values alone.

Current Replication Search: Status on 29 September 2026

This course uses a targeted current-literature search of PubMed, PubMed Central, publisher pages, and general scholarly web indexing for combinations of FGF17 or Fgf17, aging, young CSF, oligodendrocyte, oligodendrogenesis, myelin, memory, and replication. It is not a preregistered systematic review, so absence from this search is not proof that no relevant report exists.

No direct independent study was located that reproduced the full core context: naturally aged wild-type mice, young-CSF or Fgf17 intervention, aged hippocampal oligodendrocyte or myelin endpoints, and the remote-memory phenotype with a comparable design. That is the most important replication boundary.

Mechanistic Extension Is Not Independent Replication

A 2024 PNAS study, “SRF transcriptionally regulates the oligodendrocyte cytoskeleton during CNS myelination,” DOI 10.1073/pnas.2307250121, included overlapping investigators from the 2022 work. It provided strong mechanistic evidence that oligodendrocyte-lineage SRF regulates cytoskeletal programs and developmental myelination. This extends the SRF mechanism, but because it is not an independent repeat of the aged Fgf17 intervention, it should not be counted as direct replication.

Independent Cross-Model Corroboration

A 2024 ischemic-stroke study reported that recombinant human FGF17 reduced infarct-related deficits and blood–brain–barrier disruption in a mouse MCAO model, with evidence involving FGFR3 and PI3K–AKT signaling: Huang et al. 2024. This supports biological activity of FGF17 in an injured adult brain, but the principal cell target and disease context differ from normal aging.

A 2026 independent study in Neurotherapeutics, “FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits,” used Fgf17 genetic loss and intranasal recombinant FGF17 in a focal ischemia model and reported improved functional outcomes together with oligodendrogenesis and myelin-repair evidence involving Erk–SRF: Li et al. 2026. This is meaningful independent mechanistic corroboration for an FGF17–oligodendroglial repair axis, but stroke repair is not a replication of physiological brain aging.

A 2026 Brain Research article available online before its October issue reported lower serum FGF17 in people with Alzheimer disease and FGF17-related improvements in APP/PS1 mouse and cell models, with evidence involving FGFR3–PI3K–AKT: Wang et al. 2026. Again, this is disease-model corroboration, not demonstration that FGF17 reverses normal human aging.

The correct synthesis is therefore: the FGF17 signal has gained cross-model biological support, but same-context independent replication of the 2022 molecular-rejuvenation claim was not located in this search.

Human Evidence: Association Is Not Rejuvenation

Iram et al. displayed age-related FGF17 signals in healthy human CSF using age bins of 20–40 years, 40–60 years, and 60–85 years with 30, 23, and 36 samples respectively. The underlying healthy-aging CSF proteomic resource was Baird et al. 2012, “Age-Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off-Rate Modified Aptamer Array,” DOI 10.1016/j.ajpath.2011.10.024. That parent study measured hundreds of proteins in 90 cognitively normal adults aged 21–85 years and emphasized relative SOMAmer signals rather than calibrated absolute concentrations.

This supports an age association: the measured FGF17-related CSF signal varies with age. It does not establish that lower FGF17 causes cognitive aging, that restoring FGF17 reverses aging in people, or that an individual patient with low FGF17 would benefit from supplementation.

Later reports of lower serum FGF17 in ischemic stroke or Alzheimer disease are also associations embedded in disease contexts. They may generate hypotheses about biomarker biology, but serum is not CSF, disease is not normal aging, and a cross-sectional concentration difference is not a treatment effect.

Causal Design Workshop

Necessity Test: Is FGF17 Required for Young-CSF Benefit?

A direct aged-mouse necessity experiment should randomize naturally aged mice to artificial CSF, young CSF plus control antibody, and young CSF plus validated Fgf17 neutralization. Outcomes should be preregistered separately for OPC proliferation, lineage differentiation, myelin structure, remote memory, and general-performance controls.

A convincing necessity result would require selective loss of the young-CSF benefit when Fgf17 is neutralized, together with evidence that the antibody achieved adequate target engagement and did not nonspecifically damage the animals. If young CSF remains effective, Fgf17 may be redundant, partially contributory, or unnecessary under that protocol.

A stronger cellular-localization test would combine aged intervention with inducible cell-type-specific receptor deletion. For example, an OPC-lineage Fgfr3 deletion could test whether FGF17 requires FGFR3 in OPCs, while an astrocyte-specific comparison could examine an alternative target compartment. Parallel inducible Srf deletion in the oligodendrocyte lineage could test downstream pathway necessity.

Sufficiency Test: How Much Can FGF17 Reproduce by Itself?

Sufficiency requires an intervention with FGF17 alone against an appropriate vehicle control. A rigorous replication should use multiple doses, pharmacokinetic and pharmacodynamic measurements, blinded allocation and assessment, both sexes, and a route that can be compared with the original intracerebroventricular infusion.

Pre-specify distinct endpoints:

Cell proliferation: OPC entry into the cell cycle.
Cell differentiation: Fate-mapped transition toward mature oligodendrocytes.
Myelin: MBP plus ultrastructural measures such as myelinated-axon fraction and g-ratio.
Memory: Remote cued recall plus at least one non-fear memory assay.
General performance: Sensory, motor, anxiety-like, locomotor, and health controls.

A downstream sufficiency experiment could activate SRF or a validated SRF-dependent cytoskeletal program selectively in aged OPCs without FGF17. If this reproduces the oligodendroglial phenotype, it would help position SRF in the causal chain rather than merely as a correlated response.

Mediation Test: Does Oligodendrogenesis or New Myelin Cause the Memory Effect?

A mediator must sit between treatment and outcome. Temporal ordering alone is not enough. The strongest design combines treatment with a targeted perturbation of the proposed mediator.

One candidate design uses an inducible OPC-lineage block of differentiation, such as conditional disruption of a gene required for maturation, while administering FGF17 or young CSF. If the intervention still activates upstream signaling but can no longer generate new oligodendrocytes or myelin, you can ask whether the memory benefit also disappears.

A useful temporal sequence is:

Signal transduction: Measure receptor engagement, ERK or relevant proximal signaling, SRF activation, and cytoskeletal targets early.
OPC proliferation: Measure cell-cycle entry next.
Lineage tracing: Quantify the production and survival of new oligodendrocytes.
Myelin ultrastructure: Measure new or altered myelin after sufficient maturation time.
Behavior: Test memory only after the proposed mediator has had time to emerge.

Statistical mediation analysis can estimate whether measured mediator variation is compatible with an indirect effect, but it cannot substitute for mediator manipulation when unmeasured confounding is plausible. A rescue experiment is especially informative: if Fgf17 blockade removes young-CSF benefit, restore a validated downstream pathway selectively and test whether the phenotype returns.

General-Performance Control Panel

To interpret freezing as memory, add controls for shock reactivity and nociception, auditory and visual cue detection, baseline freezing, locomotion, open-field exploration, anxiety-like behavior, rotarod or gait, body weight, sickness behavior, and investigator-blinded scoring. These controls do not “prove cognition,” but they reduce alternative explanations for behavioral change.

Also use at least one memory task that does not depend on freezing. Convergent results across different response modalities make a generalized memory interpretation more credible than a single fear-conditioning endpoint.

Long-Term Follow-Up

A seven-day intervention can produce a transient molecular response without durable rejuvenation. A long-term study should therefore follow animals after treatment withdrawal at approximately one week, three weeks, three months, and six months, with survival-aware planning.

Track:

Cell fate: Persistence, differentiation, and survival of labeled OPC descendants.
Myelin structure: Myelinated-axon fraction, g-ratio, internode or nodal organization, and region specificity.
Circuit physiology: Conduction or electrophysiological measures where feasible.
Behavior: Memory, learning, motor, sensory, anxiety-like, and daily-function proxies.
Durability: Whether effects persist after FGF17 is no longer present.
Safety: Gliosis, abnormal proliferation, neuropathology, systemic organ effects, immune responses, body mass, and mortality.
Generalisability: Females and males, different ages, strains, and relevant comorbidities.

Long-term follow-up is also essential for translation because a growth-factor intervention may have effects that are adaptive in one cell state but undesirable in another. Dedicated toxicology, biodistribution, receptor selectivity, and dose-ranging studies are prerequisites before clinical efficacy claims are justified.

Claim Audit

The grading system below is intentionally evidence-specific rather than a score of the paper as a whole.

Grade A means direct evidence for the stated claim with independent same-context replication or exceptionally convergent causal evidence. Grade B means direct causal evidence in the target animal context but no direct independent same-context replication located. Grade C means association, indirect evidence, or corroboration in a materially different context. Grade D means biologically plausible but a key causal link is untested. Grade E means no direct evidence for the claim in the stated population or intervention context.

Mouse Findings

Claim	Grade	What supports it	Main boundary
Young mouse CSF increases hippocampal OPC proliferation in aged male mice	B	Direct controlled intervention in the 2022 aged-mouse study	Single core study; same-context independent replication not located
Young mouse CSF increases hippocampal myelin-related structure after maturation time	B	Increased MBP signal and more myelinated axons by electron microscopy after young-CSF exposure	Regional and sample-size limits; does not identify which CSF molecule caused the myelin effect
Fgf17 alone is sufficient to increase aged hippocampal OPC proliferation	B	Recombinant Fgf17 infusion increased OPC proliferation in aged mice	Direct same-context independent replication not located
Fgf17 alone is sufficient to improve the reported remote cued fear-memory readout in aged mice	B	Controlled aged-mouse recombinant-Fgf17 intervention in 2022	One behavioral paradigm; not broad cognition
Fgf17 alone is sufficient to increase aged-brain myelination in vivo	D	In-vitro differentiation and later cross-model myelin-repair evidence are compatible	The 2022 aged-mouse Fgf17 arm did not directly demonstrate the same in-vivo myelin endpoint
Fgf17 is necessary for the rejuvenating effect of young CSF in aged mice	D	Young-mouse antibody blockade and OPC-culture blockade support pathway participation	No direct aged young-CSF plus Fgf17-neutralization necessity test in the core paper
Oligodendrogenesis or new myelin mediates the memory benefit	D	Temporal and mechanistic coherence makes the hypothesis plausible	No mediator-blocking experiment showed that preventing new oligodendrocytes or myelin eliminates memory benefit
FGF17 produces broad general-performance rejuvenation in aged mice	D	Selected cognitive-like effects are reported	Aged Fgf17 evidence is not a broad cognitive, sensory, motor, and functional battery
FGF17 has biologic activity in other adult mouse brain-injury models	C	Independent 2024 and 2026 stroke studies and a 2026 Alzheimer-model report	Injury and transgenic disease are not physiological aging

Human Associations

Claim	Grade	What supports it	Main boundary
Healthy human CSF FGF17-related signal declines across age groups	C	Cross-sectional healthy-aging CSF proteomic association used in the 2022 paper	Association does not establish causality or treatment responsiveness
FGF17 differences are reported in human neurological disease	C	Lower serum FGF17 has been reported in ischemic stroke and Alzheimer-disease cohorts	Serum is not CSF; disease associations may reflect consequence, cause, confounding, or treatment context
Human FGF17 level predicts individual cognitive aging	D	Age associations motivate the hypothesis	Prospective validated prediction evidence is insufficient
Raising FGF17 improves memory in older humans	E	No human intervention evidence located	No clinical efficacy trial establishes this claim

Hypothetical Clinical Transport

Clinical proposition	Grade	What is presently plausible	What is still required
FGF17 could become a biomarker of aspects of brain aging	D	Age and disease associations make biomarker development testable	Assay calibration, reference ranges, longitudinal validation, specificity, and independent cohorts
FGF17 could be delivered non-invasively to influence the aging human brain	D	Intranasal activity in a 2026 mouse stroke model improves route plausibility	Human pharmacokinetics, brain exposure, dose, target engagement, reproducibility, and safety
FGF17 treatment can rejuvenate cognition in healthy older adults	E	Preclinical mouse data justify research questions	Human randomized trials do not yet establish benefit
FGF17 treatment is safe for chronic use in older adults	E	No direct chronic-human safety evidence	Long-term toxicology, off-target signaling, abnormal proliferation surveillance, immunogenicity, and dose-response studies
The 2022 mouse findings justify clinical anti-aging use now	E	They justify mechanistic and translational research	Species, route, endpoint, replication, mediation, durability, and safety gaps remain

Why “Rejuvenation” Needs an Operational Definition

“Rejuvenation” can mean movement of a molecular marker toward a younger average, restoration of a specific cell function, recovery of a tissue property, improvement of one behavioral endpoint, or reduction of age-related morbidity. These are not interchangeable.

For this topic, a rigorous rejuvenation claim should specify:

Target variable: What exactly becomes more youthful?
Reference: Compared with what young and old distributions?
Magnitude: How large is the shift and how uncertain is it?
Duration: Does it persist after treatment stops?
Function: Does the molecular change improve an independently meaningful function?
Trade-off: Are there new harms or losses elsewhere?
Generalisability: Does the effect hold across sex, age, genotype, and disease state?

A molecule can normalize one aged molecular feature while producing no meaningful organism-level benefit. Conversely, a useful treatment need not make the organism globally “younger.” Translational precision is improved when you replace the broad label with the actual measured endpoint.

Expert Colloquium: A Reproducible Replication Blueprint

Imagine a multicentre preregistered study with one discovery site and two independent replication sites. Use naturally aged mice of both sexes. Randomize within sex and age blocks, conceal allocation, blind surgery and outcome scoring where feasible, preregister exclusions, and define a primary endpoint for each mechanistic layer rather than pooling them into one narrative.

A factorial design could compare vehicle, young CSF, FGF17, young CSF plus FGF17 neutralization, and FGF17 plus a lineage-specific mediator blockade. Power the study for the primary behavioral outcome and separately for the primary myelin outcome, accounting for aging-related attrition. Replication sites should receive the locked protocol and analysis plan before seeing discovery-site outcome data.

The best result is not necessarily a significant P value. The most informative result is one that narrows the causal model: for example, young CSF still improves memory when new oligodendrocytes are blocked would argue against the proposed oligodendroglial mediator, while loss of the effect under a selective mediator perturbation would strengthen it.

Source-Critical Reading Set

Iram 2022: Primary report — Nature DOI and PubMed Central full text.
Published correction: Corrected statistical reporting — Nature Author Correction.
Human CSF proteomics: Healthy-aging association resource — Baird et al. 2012.
SRF and myelination: Mechanistic extension — PNAS 2024.
FGF17 and stroke: Adult injury-context corroboration — European Journal of Pharmacology 2024.
FGF17 oligodendrogenesis after stroke: Independent cross-model corroboration — Neurotherapeutics 2026.
FGF17 and Alzheimer models: Disease-context association and intervention work — Brain Research 2026.
Open data: The 2022 study reports sequencing data under GEO accession GSE198008.

Interactive Tasks

Quiz: Test Your Knowledge

Diesen aiMOOC als Battle spielen

Which aged-mouse behavioral effect was directly reported after young-CSF infusion in the remote test? (Higher remote cued fear-memory freezing) (!Broad improvement across all cognitive domains) (!Faster running speed) (!Improved contextual freezing on day 22)

Which observation most directly assessed myelination after young-CSF treatment? (More myelinated axons by electron microscopy) (!More OPCs entering the cell cycle) (!Higher freezing after the cue) (!Lower serum FGF17)

What did recombinant Fgf17 directly demonstrate in aged mice in the 2022 study? (Sufficiency for OPC proliferation and the remote memory readout) (!Necessity for every effect of young CSF) (!Human clinical efficacy) (!Guaranteed long-term remyelination)

Why does anti-Fgf17 treatment in young mice not establish Fgf17 necessity for young-CSF benefit in aged mice? (It tests normal young-mouse function rather than blockade of the aged rejuvenation effect) (!The antibody experiment used only human participants) (!The experiment measured no behavior) (!The experiment delivered young CSF to older adults)

What happened to the reported value in Figure 2i in the published correction? (It was corrected to 0.011 with a two-way ANOVA analysis) (!It was deleted because the experiment was fabricated) (!It was changed to a human clinical endpoint) (!It was replaced by a survival analysis)

What does the 2024 SRF myelination paper contribute most directly? (Mechanistic evidence for an oligodendrocyte SRF role in myelination) (!Independent replication of FGF17 treatment in naturally aged mice) (!A randomized human trial of FGF17) (!Proof that all memory changes require myelin)

What was the status of direct independent same-context replication in the targeted search through September 2026? (No direct independent same-context replication was located) (!Several randomized human replications were complete) (!The original paper had been formally retracted) (!Every endpoint had been reproduced in older adults)

What does an age-related FGF17 signal in healthy human CSF establish by itself? (An association between age and the measured FGF17 signal) (!That low FGF17 causes cognitive aging) (!That FGF17 treatment reverses human aging) (!That serum and CSF are interchangeable)

Which experiment would most strongly test whether new oligodendrocytes mediate an FGF17 memory effect? (Block oligodendrocyte maturation during FGF17 treatment and test whether the memory benefit disappears) (!Measure FGF17 and memory once in the same animals) (!Compare two published review articles) (!Increase the sample size without manipulating the mediator)

Which statement best reflects the current clinical evidence? (Human cognitive rejuvenation efficacy of FGF17 remains untested) (!FGF17 is an established anti-aging medicine) (!Intracerebroventricular FGF17 is approved for healthy aging) (!Mouse fear conditioning proves human dementia prevention)

Memory Game

OPC	Progenitor cell that can proliferate and enter the oligodendrocyte lineage
Myelin	Multilamellar membrane structure that ensheaths many central nervous system axons
FGF17	Growth factor nominated as a young-CSF signaling candidate
SRF	Transcription factor linked to cytoskeletal gene regulation
Necessity	Causal property tested by removing or blocking a candidate factor
Sufficiency	Causal property tested by adding a candidate factor to reproduce an effect
Mediation	Claim that an intermediate process carries part of a treatment effect to an outcome

Drag and Drop

Match the correct terms.	Topic
OPC proliferation	Early oligodendrocyte-lineage cellular response
Electron microscopy	Structural assessment of myelinated axons
Remote cued freezing	Behavioral readout used in the aged-memory experiment
Neutralization in aged recipients	Direct strategy for testing FGF17 necessity for young-CSF benefit
Mediator blockade	Strategy for testing whether oligodendrogenesis causes the memory effect

...

Crossword Puzzle

Myelin	What multilamellar structure surrounds many central nervous system axons?
Hippocampus	Which brain region was central to the molecular and cellular analyses?
Oligodendrocyte	Which mature glial cell type produces central nervous system myelin?
Mediation	What causal concept asks whether an intermediate process carries a treatment effect?
Sufficiency	What property is tested by adding a candidate factor and asking whether it reproduces an effect?
Replication	What process independently tests whether a finding can be reproduced?

LearningApps

Cloze Text

In the 2022 study, young CSF increased proliferation of hippocampal

in aged mice. Structural myelin evidence after young-CSF exposure included MBP staining and

. Recombinant Fgf17 was sufficient for selected aged-mouse endpoints but its necessity for the young-CSF effect in aged mice was not directly

. The remote behavioral effect was based on

rather than a broad cognitive battery. A human age association with FGF17 does not by itself establish

. A strong mechanism test would perturb the proposed

while preserving the upstream intervention. Same-context independent replication was not located in the targeted search through

. Clinical rejuvenation with FGF17 in humans therefore remains

.

Open-Ended Tasks

Easy

Outcome ladder: Create a one-page diagram that separates OPC proliferation, oligodendrocyte differentiation, myelin structure, remote memory recall, and general performance; mark which transitions require additional evidence.
Correction check: Read the published correction and write a 250-word note explaining why correcting P values changes the evidence record without automatically deciding the biological conclusion.
Behavior audit: Make a table of at least six non-memory factors that could alter freezing and pair each with a control measurement.
Media explanation: Record a three-minute audio or video explanation of how an oligodendrocyte differs from an OPC and why neither term is identical to myelin.

Standard

Replication map: Search PubMed or another scholarly index for post-2022 FGF17 studies and classify each as direct replication, mechanistic extension, cross-model corroboration, or unrelated evidence.
Necessity protocol: Draft an aged-mouse young-CSF plus FGF17-neutralization experiment with groups, randomization, blinding, target-engagement checks, and preregistered outcomes.
Mediation diagram: Draw a directed acyclic graph linking treatment, FGF17 signaling, SRF, OPC proliferation, oligodendrocyte maturation, myelin, memory, and key confounders; explain which arrows the 2022 data test.
Human association critique: Write a structured critique of the healthy human CSF age association, separating measurement validity, confounding, temporal direction, and clinical relevance.

Advanced

Factorial causal study: Design a factorial experiment combining young CSF, FGF17, FGF17 blockade, and an oligodendrocyte-lineage mediator perturbation; specify the causal contrast for each hypothesis.
Long-term follow-up: Produce a six-month follow-up protocol including lineage tracing, ultrastructural myelin outcomes, electrophysiology, behavior, toxicology, survival, and preplanned missing-data handling.
Cross-species translation: Build a translational evidence matrix that compares mouse aging, stroke models, Alzheimer models, healthy-human associations, and a hypothetical phase-one study without merging their evidentiary levels.
Colloquium defense: Conduct a mock expert panel in which one participant defends the strongest causal interpretation, one argues for alternative explanations, one focuses on replication, and one evaluates clinical transport; finish with a consensus list of experiments rather than a consensus verdict.

Learning Assessment

Causal reconstruction: Given a shuffled set of 2022 experiments, reconstruct their temporal and logical order and identify which results are causal interventions, mechanistic assays, associations, or behavioral outcomes.
Endpoint separation: Evaluate a fictional press release claiming that FGF17 “regrows myelin and restores cognition”; rewrite it so every statement matches the directly measured 2022 endpoints.
Necessity versus sufficiency: Compare the aged Fgf17 infusion and young-mouse anti-Fgf17 experiments and explain precisely why they answer different causal questions.
Mediation reasoning: Predict the implications of four possible outcomes from an FGF17 plus oligodendrocyte-maturation blockade experiment and state which outcomes would support or weaken myelin mediation.
Replication judgment: Classify the 2024 and 2026 FGF17 studies by context and independence, then explain why cross-model corroboration can increase plausibility without reproducing the original aging claim.
Translation dossier: Draft the minimum preclinical evidence package you would require before a first-in-human FGF17 exposure study and distinguish safety objectives from efficacy objectives.

Evidence of Learning

Evidence of learning should demonstrate that you can preserve distinctions while integrating evidence. Strong performance includes accurate reconstruction of the 2022 intervention and its correction; explicit separation of OPC proliferation, differentiation, myelination, remote cued recall, and general performance; correct use of necessity, sufficiency, and mediation; a transparent current replication search; and a claim audit that does not transport mouse causality into human efficacy.

Your products may include a preregistered replication protocol, causal diagram, corrected statistical audit, literature-classification matrix, long-term follow-up plan, or translational evidence dossier. High-quality work should identify what observation would falsify your preferred mechanism, not only what result would support it.

Transfer is demonstrated when you can apply the same framework to another molecular-rejuvenation claim: define the endpoint, identify the intervention, locate the causal contrast, separate mediator from correlate, test durability, search for independent replication, and downgrade claims appropriately when moving from animals to human association or clinical treatment.

OERs on the Topic

Useful open educational starting points include FGF17, Cerebrospinal fluid, Oligodendrocyte, Myelin, Hippocampus, Memory consolidation, Causal inference, and Translational medicine. For the primary evidence, prefer the corrected journal record and the open PubMed Central version of the 2022 study over secondary summaries.

Linked Learning Areas

Aging – FGF17 and the limits of molecular rejuvenation

aiMOOC Projects

Inhalte werden geladen ...

Mediathek wird aus dem Wiki geladen ...

Frag mich zum aktuellen Lerninhalt oder wähle eine kurze Hilfe.

Textmodus bereit

Sprache